Nacubactam - Roche

Drug Profile

Nacubactam - Roche

Alternative Names: FPI-1459; OP-0595; RG 6080; RO 7079901

Latest Information Update: 09 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Fedora Pharmaceuticals
  • Developer Meiji Seika Pharma; Roche
  • Class Antibacterials; Azabicyclo compounds
  • Mechanism of Action Beta lactamase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Bacterial infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Bacterial-infections(In volunteers) in Australia (IV, Injection)
  • 28 Jul 2017 Roche completes a phase I pharmacokinetic trial (Combination therapy) in USA (IV) (NCT03182504)
  • 11 Jul 2017 Roche initiates enrolment in a phase I pharmacokinetic trial (Combination therapy) in USA (IV) (NCT03174795)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top